Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 1
2007 2
2010 2
2011 1
2018 1
2020 4
2021 6
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T. Shimose S, et al. Among authors: yamaguchi t. Sci Rep. 2022 Oct 11;12(1):17018. doi: 10.1038/s41598-022-21528-2. Sci Rep. 2022. PMID: 36220865 Free PMC article.
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.
Suzuki H, Iwamoto H, Shimose S, Niizeki T, Shirono T, Noda Y, Kamachi N, Yamaguchi T, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Suzuki H, et al. Among authors: yamaguchi t. Front Oncol. 2022 Jul 22;12:948293. doi: 10.3389/fonc.2022.948293. eCollection 2022. Front Oncol. 2022. PMID: 35936693 Free PMC article.
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. Shimose S, et al. Among authors: yamaguchi t. Cancer Med. 2021 Dec;10(23):8530-8541. doi: 10.1002/cam4.4367. Epub 2021 Oct 24. Cancer Med. 2021. PMID: 34693661 Free PMC article.
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: yamaguchi t. Cancers (Basel). 2021 Jun 3;13(11):2786. doi: 10.3390/cancers13112786. Cancers (Basel). 2021. PMID: 34205099 Free PMC article.
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma.
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Iwamoto H, et al. Among authors: yamaguchi t. Cancers (Basel). 2021 Feb 5;13(4):646. doi: 10.3390/cancers13040646. Cancers (Basel). 2021. PMID: 33562793 Free PMC article.
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: yamaguchi t. Cancers (Basel). 2021 Jan 5;13(1):160. doi: 10.3390/cancers13010160. Cancers (Basel). 2021. PMID: 33466496 Free PMC article.
Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.
Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: yamaguchi t. Oncol Lett. 2020 Sep;20(3):2257-2265. doi: 10.3892/ol.2020.11758. Epub 2020 Jun 19. Oncol Lett. 2020. PMID: 32782543 Free PMC article.
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: yamaguchi t. Cancers (Basel). 2020 Jul 11;12(7):1867. doi: 10.3390/cancers12071867. Cancers (Basel). 2020. PMID: 32664489 Free PMC article.
24 results